SCHEMBL633682

SCHEMBL633682

[CH2]C1CCN(CCOC)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.41
HSD11B1 P28845 1/20 0.39
ALDH1A1 P00352 1/20 0.37
GBA1 P04062 2/20 0.37
NPC1 O15118 1/20 0.36
HRH1 P35367 1/20 0.36
PARP1 P09874 2/20 0.34
SIGMAR1 Q99720 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNA2 P20248 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CCND3 P30281 1/20 0.33
CDK6 Q00534 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
BRD4 O60885 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515286 0.88 GBA1 (0.39) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL14487940 0.81 KDM1A (0.40) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL1570155 0.80 HSD11B1 (0.44) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL26031963 0.80 KDM1A (0.42) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL12607 0.80 ALDH1A1 (0.53) ALDH1A1SIGMAR1KMT2A
SCHEMBL18776398 0.80 KDM1A (0.42) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL7740824 0.79 NPC1 (0.47) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL4380526 0.79 KDM1A (0.39) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL19983442 0.78 KDM1A (0.41) KDM1AHSD11B1ALDH1A1GBA1NPC1
SCHEMBL4761260 0.78 KDM1A (0.41) KDM1AHSD11B1ALDH1A1GBA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP claimed
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2018-10-11 US claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP claimed
EP-3286172-A1 LSD1 INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2018-02-28 EP claimed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 US claimed
EP-2222648-B1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS ASTRAZENECA AB (SE) 2013-01-09 EP claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
EP-2234992-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2012-02-22 EP claimed
US-20110275670-A1 New Compounds VII BIOVITRUM AB (SE) 2011-11-10 US claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
US-6759428-B2 SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS ROCHE PALO ALTO LLC 2004-07-06 US claimed
US-20040077646-A1 Indole nitriles ROCHE PALO ALTO LLC 2004-04-22 US claimed
US-11771695-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 US disclosed
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2022-08-04 US disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM1A 2127/4885HSD11B1 3497/4885ALDH1A1 3623/4885
US-20040077646-A1 Indole nitriles TPH1, IDO1, NAT1 KDM1A 1030/4885HSD11B1 694/4885ALDH1A1 535/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 KDM1A 2127/4885HSD11B1 3497/4885ALDH1A1 3623/4885
US-20220241274-A1 CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 KDM1A 3003/4885HSD11B1 2396/4885ALDH1A1 2692/4885
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF KDM1B, KDM1A, KDM2A KDM1A 2/4885HSD11B1 551/4885ALDH1A1 187/4885
US-20110275670-A1 New Compounds VII GPR119, GLP1R, GIPR KDM1A 3463/4885HSD11B1 1002/4885ALDH1A1 2629/4885
US-11771695-B2 Cannabinoid receptor modulators CNR2, CNR1, OPRL1 KDM1A 3003/4885HSD11B1 2396/4885ALDH1A1 2692/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM1A 2127/4885HSD11B1 3497/4885ALDH1A1 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.